Invention Grant
- Patent Title: Optimized anti-TL1A antibodies
-
Application No.: US16863971Application Date: 2020-04-30
-
Publication No.: US11440954B2Publication Date: 2022-09-13
- Inventor: Jeffry D. Watkins , Cindy T. Dickerson , J. Monty Watkins , Patricia McNeeley , Janine Bilsborough , Bradley Henkle , Stephan R. Targan
- Applicant: Prometheus Biosciences, Inc. , Cedars-Sinai Medical Center
- Applicant Address: US CA San Diego; US CA Los Angeles
- Assignee: Prometheus Biosciences, Inc.,Cedars-Sinai Medical Center
- Current Assignee: Prometheus Biosciences, Inc.,Cedars-Sinai Medical Center
- Current Assignee Address: US CA San Diego; US CA Los Angeles
- Agency: Wilson Sonsini Goodrich & Rosati
- Main IPC: C07K16/24
- IPC: C07K16/24 ; C07K16/28 ; C12N5/10 ; C12N15/09 ; C12N15/63 ; A61P1/04 ; A61P1/00 ; A61K9/00 ; C07K14/525 ; C07K14/715 ; A61K39/395 ; A61K39/00
Abstract:
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohn's Disease (CD) and ulcerative colitis (UC).
Public/Granted literature
- US20200255510A1 OPTIMIZED ANTI-TL1A ANTIBODIES Public/Granted day:2020-08-13
Information query
